B&A Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Accelerator/​Inc

B&A Therapeutics General Information

Description

Developer of novel therapies intended to treat neurological diseases. The company uses a variety of scientific approaches, including gene therapy, cell therapy, and small molecule drugs, to develop new medicines for neurological and neurodegenerative diseases such as Parkinson's and Huntington's, enabling healthcare providers to have access to new medicines to treat patients with these debilitating conditions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Biotech Beret-Delaage Case 922
  • 163 Avenue de Luminy
  • 13009 Marseille
  • France

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

B&A Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator Completed Startup
To view B&A Therapeutics’s complete valuation and funding history, request access »

B&A Therapeutics Patents

B&A Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4311548-A1 Combination of a nkcc1 protein inhibitor and a microtubule inhibitor for use in the treatment of cancer Pending 29-Jul-2022 0000000000 0
US-20160312229-A1 Modulators of intracellular chloride concentration for treating down syndrome Active 20-Dec-2013 00000000000 0
EP-3083959-A1 Modulators of intracellular chloride concentration for treating down syndrome Active 20-Dec-2013 00000000000
EP-3083959-B1 Inhibitors of intracellular chloride concentration for treating down syndrome Active 20-Dec-2013 00000000000
JP-6490077-B2 Modulator of intracellular chloride concentration for treating down's syndrome Active 20-Dec-2013 C12N15/1138
To view B&A Therapeutics’s complete patent history, request access »

B&A Therapeutics Executive Team (10)

Name Title Board Seat Contact Info
Yehezkel Ben-Ari Ph.D Co-Founder, President & Chief Executive Officer
Denis Ravel Co-Founder & Managing Director
Philippe Damier Ph.D Principal Investigator
Jean-Christophe Corvol Executive
Constance Hammond Co-Founder
You’re viewing 5 of 10 executive team members. Get the full list »

B&A Therapeutics FAQs

  • When was B&A Therapeutics founded?

    B&A Therapeutics was founded in 2014.

  • Who is the founder of B&A Therapeutics?

    Yehezkel Ben-Ari Ph.D, Denis Ravel, Constance Hammond, Diana Ferrari, Eric Lemonnier, Nathalie Dehorter Ph.D, Nouchine Hadjikhani, and Romain Nardou are the founders of B&A Therapeutics.

  • Who is the CEO of B&A Therapeutics?

    Yehezkel Ben-Ari Ph.D is the CEO of B&A Therapeutics.

  • Where is B&A Therapeutics headquartered?

    B&A Therapeutics is headquartered in Marseille, France.

  • What industry is B&A Therapeutics in?

    B&A Therapeutics’s primary industry is Drug Discovery.

  • Is B&A Therapeutics a private or public company?

    B&A Therapeutics is a Private company.

  • What is B&A Therapeutics’s current revenue?

    The current revenue for B&A Therapeutics is 000000.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »